ZyVersa Therapeutics Inc. and Larkspur Health Acquisition Corp. Close Business Combination; ZyVersa Expected to Begin Trading on Nasdaq December 13, 2022 (Ticker “ZVSA”)

ZyVersa is a clinical-stage biopharmaceutical company developing first-in-class product candidates for the treatment of kidney and inflammatory diseases.

Weston, Fla. and Bridgewater, NJ, December 12, 2022 /PRNewswire/ — ZyVersa Therapeutics, Inc. (“ZyVersa”), a clinical-stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop products for patients with kidney or inflammatory diseases with high medical needs, and Larkspur Health Achievement Corporation ( NASDAQ) : LSPR or “Larkspur”), a blank check special purpose acquisition company, is pleased to announce the closing of their previously announced business combination.

The business combination and related transactions were approved by Larspur’s stockholders at a special meeting. 8th December 2022. The joint venture will be ZyVersa Therapeutics, Inc. Work as, under the former management team of ZyVersa, headed by Stephen C. GloverCo-Founder, CEO, and President of ZyVersa. Daniel J. O’Connor, who was chairman and CEO of Larspur, will join the board of directors of Ziorsa. ZyVersa common stock is expected to begin trading on the Nasdaq under the ticker symbols “ZVSA.” 13 December 2022. Larkspur warrants previously traded under the symbol “LSPRW” will no longer be listed for trading on the Nasdaq.

“Today marks an important milestone for ZyVersa. We are pleased to close our business combination with Larkspur and begin our next chapter as a publicly traded company,” said Mr. Glover. “I want to thank our shareholders at Larkspur, our board of directors, and my colleagues at ZyVersa for helping make this possible. Funding from this transaction allows ZyVersa to continue our expansion of the VAR 200 “Take steps to advance the clinical program, cholesterol efflux mediators, to new drug applications for patients with kidney disease, and to develop IC 100, an inhibitor of the inflammatory ASC,” Mr. Glover said. continued

“We are pleased to partner with ZyVersa in this business combination,” said Mr. O’Connor. “We believe ZyVersa has the potential to create stockholder value based on its unique value proposition as discussed in public filings,” Mr. O’Connor continued.


Benchmark Company LLC and Noble Capital Markets, Inc. are acting as financial advisors to ZyVersa, and Lowenstein Sandler LLP is acting as legal counsel to ZyVersa.

AGP/Alliance Global Partners, with Manatt, Phelps & Phillips, LLP acting as legal counsel, is serving as exclusive financial advisor to Larkspur. Alston & Bird LLP is serving as Larkspur’s legal counsel.

About Larkspur Health Acquisition Corp.

Larkspur is a special purpose acquisition company (SPAC) created to identify a biopharmaceutical company that can grow and develop as a newly formed public company, and benefit from Larkspur’s operating expertise and significant investment. Larspur’s management team and members of the board of directors have participated in previous management and executive leadership teams of private and/or public biopharmaceutical companies and they collectively have more than 50+ years of cumulative investment and operational experience. The team strongly believes in the growth opportunities in the biotechnology industry. They are experienced operators seeking to partner with top innovators and thinkers in the biopharmaceutical sector. Their entrepreneurial approach supports management teams in making impactful decisions towards growth and operational excellence. For more information, please visit www.lsprhealth.com.

About ZyVersa Therapeutics, Inc.

ZyVersa is a clinical-stage specialty biopharmaceutical company that uses advanced, proprietary technologies to develop product candidates that address high unmet medical needs in the areas of kidney and inflammatory diseases. ZyVersa’s development pipeline includes a Phase 2a-ready VAR 200, a cholesterol efflux modulator for the treatment of a rare kidney disease, focal segmental glomerulosclerosis. ZyVersa believes VAR 200 has the potential to treat other glomerular diseases, including Alport syndrome and diabetes. ZyVersa’s development pipeline also includes IC 100, a novel inflammatory ASC inhibitor developed to treat several inflammatory diseases. For more information, please visit www.zyversa.com.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements in this press release that do not contain historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Depository Reform Act of 1995. Includes qualifying statements. regarding management’s intentions, plans, beliefs, expectations, or projections for the future, and therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those anticipated. ZyVersa Therapeutics, Inc. (“ZyVersa”) uses words such as “expect,” “believe,” “plans,” “expect,” “projects,” “future,” “intends,” “may,” “will,” “should ,” “may,” “estimates,” “forecasts,” “potential,” “continuing,” “guidance,” and similar expressions to identify these forward-looking statements that are intended to be covered by the safe harbor provisions. Forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied by the statements, including ZyVersa’s plans to development and commercialization of these product candidates, the timing of initiation of planned preclinical and clinical trials of ZyVersa; the timing of the availability of data from preclinical and clinical trials of ZyVersa; any planned investigational new drug application or new drug application; Application timing; ZyVersa’s plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits, and market acceptance of ZyVersa’s product candidates; ZyVersa’s commercialization, marketing, and See capabilities and strategy; ZyVersa’s ability to protect its intellectual property position; and ZyVersa’s estimates of future revenues, expenses, capital requirements and additional financing required.

New factors arise over time, and it is not possible for ZyVersa to predict all of these factors, nor can ZyVersa predict the impact of any factor or any combination of factors on the business. to evaluate could cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.

Source: ZyVersa Therapeutics, Inc.


Leave a Reply

Your email address will not be published.